Emergent BioSolutions Inc. (EBS)
| Market Cap | 415.35M +13.9% |
| Revenue (ttm) | 676.80M -29.9% |
| Net Income | -8.60M |
| EPS | -0.21 |
| Shares Out | 51.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,205,669 |
| Open | 8.20 |
| Previous Close | 8.18 |
| Day's Range | 7.93 - 8.23 |
| 52-Week Range | 5.62 - 14.06 |
| Beta | 2.34 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+49.07%) |
| Earnings Date | Aug 5, 2026 |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for EBS stock is "Strong Buy." The 12-month stock price target is $12.0, which is an increase of 49.07% from the latest price.
News
Emergent BioSolutions awarded $52.7M contract modification
Emergent BioSolutions (EBS) announced it has been awarded a contract modification valued at $52.7M from the Administration for Strategic Preparedness and Response, or ASPR, at the United States Depart...
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for St...
BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex
AKRON, Ohio--(BUSINESS WIRE)-- #BIO2026--BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food and...
Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company leads in biodefense and opioid overdose treatments, reporting a successful turnaround with improved EBITDA, cash flow, and debt reduction. Growth is driven by product innovation, international expansion, and major government contracts, with a strong focus on R&D and capital efficiency.
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources Efforts focus on increasing awareness...
Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted its leadership in biodefense and opioid overdose solutions, reporting a successful turnaround with improved EBITDA, reduced debt, and strong Q1 2026 results. Growth is driven by international expansion, new contracts, product innovation, and a robust R&D pipeline.
Emergent BioSolutions awarded $64.5M HHS contract modification
Emergent BioSolutions (EBS) announced it has been awarded a contract modification valued at approximately $64.5M from the Administration for Strategic Preparedness and Response, or ASPR, a division of...
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Ad...
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following invest...
Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine
Emergent BioSolutions (EBS) announced that the Saudi Food and Drug Authority has approved the registration of ACAM2000 for the prevention of smallpox and mpox disease in individuals determined to be…
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the regist...
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue and EBITDA exceeded expectations, driven by strong MCM and naloxone performance, international expansion, and operational efficiency. Debt reduction, refinancing, and new partnerships strengthened the financial position, with full-year guidance maintained.
Emergent BioSolutions Earnings release: Q1 2026
Emergent BioSolutions released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Emergent BioSolutions Slides: Q1 2026
Emergent BioSolutions has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Emergent BioSolutions Quarterly report: Q1 2026
Emergent BioSolutions has published its Q1 2026 quarterly earnings report on April 30, 2026.
Emergent BioSolutions Reports First Quarter 2026 Financial Results
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2026.
Emergent BioSolutions receives Singapore regulatory approval for ACAM2000
Emergent BioSolutions (EBS) announced that Singapore’s Health Sciences Authority has approved an expanded indication for ACAM2000 to include prevention of mpox disease in adults determined to be at hi...
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for AC...
Emergent BioSolutions Transcript: AGM 2026
The meeting highlighted significant financial improvements in 2025, including higher EBITDA, reduced debt, and expanded product lines. All shareholder proposals passed, and strategic plans focus on growth, innovation, and international expansion.
Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics
Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical develop...
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support th...
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
WINNIPEG, Manitoba, April 29, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced it is teaming up with professional baseball player Davis Schneider to break down the stigma ar...
Emergent BioSolutions reports Imojev manufacturing pact with Substipharm
Emergent BioSolutions (EBS) announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5M to support drug substance manufacturing for its Japanese Encephalitis v...
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximat...